Oncoinvent A

Oncoinvent A FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Oncoinvent A (ONCIN.OL) as of Nov 7, 2026 is 84.68 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 111.32 % — a change of -23.93% (lower).

FCF Conversion

84.68 %

YoY

-23.93%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Oncoinvent A is 2025 84.68 % . FCF Conversion Rate (FCF/EBITDA) of Oncoinvent A was 2024 111.32 % . It decreases by -23.93% lower compared to the previous year.

The Oncoinvent A FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
97.49 NOK
Jan 1, 2019
93.68 NOK
Jan 1, 2020
91.18 NOK
Jan 1, 2021
98.05 NOK
Jan 1, 2022
96.72 NOK
Jan 1, 2023
86.63 NOK
Jan 1, 2024
111.32 NOK
Jan 1, 2025
84.68 NOK
The Oncoinvent A FCF Conversion history
YEARFCF ConversionYoY
84.68 %-23.93%
111.32 %+28.50%
86.63 %-10.43%
96.72 %-1.36%
98.05 %+7.54%
91.18 %-2.67%
93.68 %-3.91%
97.49 %+5.45%
92.45 %-3.67%
95.97 %+10.01%
87.24 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Oncoinvent A Stock analysis

What does Oncoinvent A do? Oncoinvent ASA is a radiopharmaceutical company based in Oslo, Norway, operating within the Health Care sector. Listed on 13 December 2024, the firm employs 46 people and focuses on developing alpha-emitting radiotherapeutics for cancer patients. Its primary product, Radspherin, is an alpha-emitting radioactive microsphere therapy designed to treat metastatic cancers in body cavities. This suspension of calcium carbonate microspheres labelled with Radium-224 targets residual micro-metastases on intracavitary surfaces and in liquids after surgery, aiming to spare deeper organs from harmful radiation doses. Oncoinvent A is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Oncoinvent A stock

FCF Conversion Rate (FCF/EBITDA) of Oncoinvent A is 84.68 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Oncoinvent A changed from 111.32 % to 84.68 %, representing a -23.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Oncoinvent A since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Oncoinvent A with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Oncoinvent A

All Key Metrics — Oncoinvent A